Susquehanna International Group, LLP I Teos Therapeutics, Inc. Call Options Transaction History

Susquehanna International Group, LLP

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$10.09 - $17.97 $736,570 - $1.31 Million	-73,000 Reduced 40.9%	105,500 $1.08 Million
Q2 2024 Aug 15, 2024	BUY	$10.33 - $18.09 $1.59 Million - $2.78 Million	153,700 Added 619.76%	178,500 $2.65 Million
Q1 2024 May 07, 2024	SELL	$9.89 - $13.64 $816,914 - $1.13 Million	-82,600 Reduced 76.91%	24,800 $338,000
Q4 2023 Feb 14, 2024	SELL	$8.57 - $11.06 $23,996 - $30,968	-2,800 Reduced 2.54%	107,400 $1.18 Million
Q3 2023 Nov 14, 2023	BUY	$10.95 - $14.6 $1.21 Million - $1.61 Million	110,200 New	110,200 $1.21 Million
Q1 2023 May 16, 2023	BUY	$13.02 - $22.62 $290,346 - $504,426	22,300 New	22,300 $303,000
Q2 2022 Aug 15, 2022	BUY	$16.57 - $35.1 $626,346 - $1.33 Million	37,800 Added 385.71%	47,600 $981,000
Q1 2022 May 16, 2022	BUY	$31.92 - $47.45 $312,816 - $465,010	9,800 New	9,800 $315,000

166

36.6M

1.95M

374K

Ticker ITOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,575,300
Market Cap $283M
Description
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.